Clinical Trial

Serum Endocan, Alarin, and Galanin-Like Peptide Levels in Diabetic Retinopathy

Completed
View on ClinicalTrials.gov →
Summary
This prospective cross-sectional study aims to evaluate the association between serum endocan, alarin, and galanin-like peptide levels and the stages of diabetic retinopathy (DR), as well as their relationship with optical coherence tomography (OCT) findings. A total of 120 participants will be included: 30 patients without diabetic retinopathy, 30 with non-proliferative diabetic retinopathy, 30 with proliferative diabetic retinopathy, and 30 healthy control subjects. In addition to routine preoperative blood sampling, an additional 5 mL of venous blood will be collected for biomarker analysis using ELISA. Macular and peripapillary retinal nerve fiber layer measurements will be obtained using OCT. Serum biomarker levels will be compared across DR stages and analyzed for correlation with OCT parameters.
Trial Details
NCT Number NCT07434362
Lead Sponsor Elazıg Fethi Sekin Sehir Hastanesi
Conditions Diabetic Retinopathy, Diabetes Mellitus, Retinal Microvascular Disease
Enrollment 90 participants
Start Date 2026-01-30
Primary Completion 2026-02-01 (estimated)
Study Completion 2026-02-18 (estimated)
Updated on ClinicalTrials.gov 2026-02-25